Trial Information
Effects of Cytotoxic Chemotherapy on Ovarian Structure and Function
OBJECTIVES:
- Determine the incidence and timing of ovarian dysfunction/damage in younger
premenopausal women undergoing cytotoxic chemotherapy for cancer.
- Determine the feasibility of a prospective, randomized study to assess if gonadotropin
analogues can protect the ovary from the cytotoxic effects of chemotherapy.
- Determine the number of patients required for adequate power to test the hypothesis.
OUTLINE: This is a pilot, prospective study.
Patients undergo a transvaginal or transabdominal ultrasound to measure the ovarian volume
and count the number of antral follicles at baseline, 3 months after beginning cytotoxic
chemotherapy, and at 6 months after completion of treatment. Patients undergo blood
collection at the same time points for follicle-stimulating hormone, estradiol, and inhibin
B levels. Patients are also asked to fill out questionnaires on estrogen-depletion symptoms
at those times. Patients also keep a calendar of menstrual bleeding and hormonal
medications.
PROJECTED ACCRUAL: A total of 22 patients will be accrued for this study.
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Diagnosis of cancer, including, but not limited to, any of the following:
- Acute lymphocytic leukemia
- Acute myeloid leukemia
- Hodgkin's lymphoma
- Must have primary disease with significant chance for long-term survival after
therapy
- Scheduled to receive chemotherapeutic agents known to be associated with ovarian
failure, including any of the following:
- Cyclophosphamide
- Mechlorethamine hydrochloride
- Busulfan
- Procarbazine hydrochloride
- Chlorambucil
- Melphalan
- Ifosfamide
- Cisplatin
- Carboplatin
- Postmenarchal and premenopausal
PATIENT CHARACTERISTICS:
- Female
- Weight ≤ 250 pounds
- Not pregnant
PRIOR CONCURRENT THERAPY:
- No prior or concurrent total-body irradiation or radiotherapy to the pelvis
- Concurrent bone marrow transplantation allowed
- Concurrent oral contraception and/or gonadotropin releasing-hormone analogue allowed
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Incidence of ovarian damage after cytotoxic chemotherapy as determined by changes in ovarian volume, antral follicle count, and follicle-stimulating hormone, estradiol, and inhibin B levels
Outcome Time Frame:
Ultrasound to measure the ovarian volume and count the number of antral follicles at baseline, 3 months after beginning cytotoxic chemotherapy, and at 6 months after completion of treatment. Patients undergo blood collection at the same time points.
Safety Issue:
No
Principal Investigator
Marjorie Greenfield, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center
Authority:
United States: Federal Government
Study ID:
CWRU3803
NCT ID:
NCT00402935
Start Date:
February 2004
Completion Date:
May 2007
Related Keywords:
- Leukemia
- Long-term Effects Secondary to Cancer Therapy in Adults
- Long-term Effects Secondary to Cancer Therapy in Children
- Lymphoma
- Sexual Dysfunction and Infertility
- Sexuality and Reproductive Issues
- Unspecified Adult Solid Tumor, Protocol Specific
- Unspecified Childhood Solid Tumor, Protocol Specific
- long-term effects secondary to cancer therapy in adults
- long-term effects secondary to cancer therapy in children
- sexual dysfunction and infertility
- sexuality and reproductive issues
- adult acute lymphoblastic leukemia in remission
- childhood acute lymphoblastic leukemia in remission
- recurrent adult acute lymphoblastic leukemia
- recurrent childhood acute lymphoblastic leukemia
- untreated adult acute lymphoblastic leukemia
- untreated childhood acute lymphoblastic leukemia
- adult acute myeloid leukemia in remission
- recurrent adult acute myeloid leukemia
- recurrent childhood acute myeloid leukemia
- untreated adult acute myeloid leukemia
- untreated childhood acute myeloid leukemia and other myeloid malignancies
- secondary acute myeloid leukemia
- stage I adult Hodgkin lymphoma
- stage I childhood Hodgkin lymphoma
- stage II adult Hodgkin lymphoma
- stage II childhood Hodgkin lymphoma
- stage III adult Hodgkin lymphoma
- stage III childhood Hodgkin lymphoma
- stage IV adult Hodgkin lymphoma
- stage IV childhood Hodgkin lymphoma
- recurrent adult Hodgkin lymphoma
- recurrent/refractory childhood Hodgkin lymphoma
- unspecified adult solid tumor, protocol specific
- unspecified childhood solid tumor, protocol specific
- childhood acute myeloid leukemia in remission
- adult acute myeloid leukemia with 11q23 (MLL) abnormalities
- adult acute myeloid leukemia with inv(16)(p13;q22)
- adult acute myeloid leukemia with t(16;16)(p13;q22)
- adult acute myeloid leukemia with t(15;17)(q22;q12)
- adult acute myeloid leukemia with t(8;21)(q22;q22)
- Infertility
- Leukemia
- Lymphoma
- Sexual Dysfunctions, Psychological
- Neoplasms
Name | Location |
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center |
Cleveland, Ohio 44106-5065 |